Ovintiv Free cash flow decreased by 7.8% to $451.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 76.2%, from $256.00M to $451.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows relatively stable performance with a -1.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $367.00M | $447.00M | $319.00M | $234.00M | $833.00M | $451.00M | $517.00M | $458.00M | $191.00M | $72.00M | $702.00M | $68.00M | $398.00M | $484.00M | $468.00M | $256.00M | $492.00M | $268.00M | $489.00M | $451.00M |
| QoQ Change | — | +21.8% | -28.6% | -26.6% | +256.0% | -45.9% | +14.6% | -11.4% | -58.3% | -62.3% | +875.0% | -90.3% | +485.3% | +21.6% | -3.3% | -45.3% | +92.2% | -45.5% | +82.5% | -7.8% |
| YoY Change | — | — | — | — | +127.0% | +0.9% | +62.1% | +95.7% | -77.1% | -84.0% | +35.8% | -85.2% | +108.4% | +572.2% | -33.3% | +276.5% | +23.6% | -44.6% | +4.5% | +76.2% |